Scarica l'app Stockscreener
11.07
2.98%
0.32
Dopo l'orario di chiusura:
11.05
-0.02
-0.18%
Precedente Chiudi:
$10.75
Aprire:
$11.14
Volume 24 ore:
3.38M
Relative Volume:
0.96
Capitalizzazione di mercato:
$1.90B
Reddito:
$1.84M
Utile/perdita netta:
$-118.44M
Rapporto P/E:
-13.35
EPS:
-0.8291
Flusso di cassa netto:
$-98.51M
1 W Prestazione:
+13.66%
1M Prestazione:
+25.80%
6M Prestazione:
+261.76%
1 anno Prestazione:
+211.83%
Intervallo 1D:
$10.83
$11.35
Intervallo di 1 settimana:
$9.25
$11.35
Portata 52W:
$2.24
$12.05
Absci Corp Stock (ABSI) Company Profile
Nome
Absci Corp
Settore
Industria
Telefono
(360) 949-1041
Indirizzo
18105 SE MILL PLAIN BLVD, VANCOUVER
Compare ABSI vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ABSI
Absci Corp
|
11.07 | 1.67B | 1.84M | -118.44M | -98.51M | -0.8291 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Absci Corp Stock (ABSI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-10-02 | Iniziato | JP Morgan | Overweight |
| 2025-07-03 | Ripresa | Morgan Stanley | Overweight |
| 2025-01-22 | Iniziato | Needham | Buy |
| 2024-10-02 | Iniziato | Guggenheim | Buy |
| 2024-07-03 | Iniziato | Morgan Stanley | Overweight |
| 2024-03-14 | Iniziato | Scotiabank | Sector Outperform |
| 2023-12-05 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2023-05-04 | Iniziato | H.C. Wainwright | Buy |
| 2022-08-12 | Downgrade | JP Morgan | Overweight → Underweight |
| 2022-07-18 | Iniziato | Truist | Buy |
| 2022-03-02 | Ripresa | Cowen | Market Perform |
| 2022-02-01 | Iniziato | Berenberg | Buy |
| 2021-11-10 | Downgrade | BofA Securities | Neutral → Underperform |
| 2021-10-15 | Ripresa | Cowen | Market Perform |
| 2021-08-16 | Iniziato | BofA Securities | Neutral |
| 2021-08-16 | Iniziato | Cowen | Market Perform |
| 2021-08-16 | Iniziato | Credit Suisse | Outperform |
| 2021-08-16 | Iniziato | Stifel | Hold |
Mostra tutto
Absci Corp Borsa (ABSI) Ultime notizie
Artificial Intelligence Stocks To Follow TodayOctober 1st - MarketBeat
Absci Corporation $ABSI Shares Newly Acquired by Bank of America Corp DE - MarketBeat
Guggenheim reiterates Absci stock rating on endometriosis trial delay - Investing.com
ABSCI Corp Agencies, 2024 - OpenSecrets
ABSI Stock Eyes Best Day Ever After Positive Hair Loss Drug Data, $100M Lilly-Backed Raise - Stocktwits
Absci (NASDAQ:ABSI) Given "Buy" Rating at Needham & Company LLC - MarketBeat
Absci Corporation (ABSI) Stock Price, News, Quote & History - Yahoo! Finance Canada
LifeSci Capital Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $16 - Moomoo
Absci Corporation Announces Preliminary Details for Phase 2 Storyline? Trial of Ai-Designed Antibody Abs-201? for Endometriosis - marketscreener.com
Absci plans phase 2 trial of ABS-201 for endometriosis in 2027 - Investing.com
Absci Expects to Initiate Mid-Stage Trial of ABS-201 for Endometriosis in Mid-2027 - Yahoo Finance
Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosis - The Manila Times
Absci Announces Preliminary Details for Phase 2 STORYLINE Trial of AI-Designed Antibody ABS-201 for Endometriosis - Moomoo
Absci (NASDAQ:ABSI) Stock Price Down 8.3%What's Next? - MarketBeat
Wall Street Analysts Predict a 28.3% Upside in ABSCI CORP (ABSI): Here's What You Should Know - Eastern Progress
Absci (ABSI) Stock Looks Expensive Against Its Book Value - Yahoo Finance
H.C. Wainwright Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $16 - Moomoo
Absci Corporation (ABSI) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Absci (NASDAQ:ABSI) Stock Price Up 12.5%Here's What Happened - MarketBeat
Artificial Intelligence Stocks Worth WatchingSeptember 17th - marketbeat.com
Absci at Morgan Stanley healthcare conference: AI platform meets clinical test - Investing.com
Squarepoint Ops LLC Sells 228,841 Shares of Absci Corporation $ABSI - MarketBeat
Baldness Drug Stocks like Veradermics (MANE) and Absci (ABSI) Are Chasing the Same Wall Street Magic as Ozempic - Yahoo Finance
Lifesci Capital Begins Coverage on Absci (NASDAQ:ABSI) - MarketBeat
LifeSci Capital Initiates Absci Corp(ABSI.US) With Buy Rating, Announces Target Price $16 - moomoo.com
Absci's Billion-Dollar Hair Bet: Why The AI Story Doesn't Add Up (NASDAQ:ABSI) - Seeking Alpha
BTIG Maintains Absci Corp(ABSI.US) With Buy Rating, Raises Target Price to $16 - moomoo.com
Absci Corporation Stock (ABSI) Opinions on Investor Conference Participation - Quiver Quantitative
Bank of New York Mellon Corp Buys Shares of 386,832 Absci Corporation $ABSI - MarketBeat
ABSI: Absci Corp Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Absci Corporation $ABSI Shares Bought by Bank of America Corp DE - MarketBeat
Absci (NASDAQ:ABSI) Stock Price Down 4.8%Should You Sell? - MarketBeat
Can Absci’s (ABSI) Low-Frequency Hair Loss Therapy Redefine Its Long-Term Platform Potential? - simplywall.st
Absci Corp CFO Zachariah Jonasson Reports RSU Tax Withholding Share Transaction - Kalkine Media
Absci to Participate in Upcoming Investor Conferences - The Manila Times
Deutsche Bank AG Acquires New Stake in Absci Corporation $ABSI - MarketBeat
Forget GLP-1 stocks, baldness drugs are Wall Street’s next goldmine - Fortune
Artia Global Partners LP Acquires Shares of 464,444 Absci Corporation $ABSI - marketbeat.com
Absci (NASDAQ:ABSI) Trading 8.5% HigherWhat's Next? - MarketBeat
Certain Common Stock of Absci Corporation are subject to a Lock-Up Agreement Ending on 24-AUG-2026. - marketscreener.com
Absci (NASDAQ:ABSI) Shares Gap UpShould You Buy? - MarketBeat
Morgan Stanley Maintains Absci Corp(ABSI.US) With Hold Rating, Raises Target Price to $10 - 富途牛牛
Absci (ABSI) Q2 2026 Earnings Call Transcript - AOL.com
Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does. - GlobeNewswire
Ransi Mudalinayake Somaratne Net Worth (2026) - GuruFocus
The Zacks Analyst Blog Highlights Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci - Zacks Investment Research
4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma - The Globe and Mail
ABSI Looks 1092.2% Overvalued on GF Value™ - GuruFocus
Absci Corp (ABSI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Absci Corporation (NASDAQ:ABSI) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Absci (NASDAQ:ABSI) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Absci Corp Azioni (ABSI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Absci Corp Azioni (ABSI) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Pangalos Menelas N | Director |
May 13 '26 |
Buy |
5.36 |
37,453 |
200,748 |
232,308 |
| Busch Andreas | Chief Innovation Officer |
Mar 12 '26 |
Buy |
2.29 |
100,000 |
229,000 |
421,446 |
| Pangalos Menelas N | Director |
Feb 27 '26 |
Buy |
2.74 |
75,095 |
205,760 |
189,055 |
| McClain Sean | Chief Executive Officer |
Feb 23 '26 |
Option Exercise |
1.21 |
396,399 |
479,643 |
8,730,966 |
| McClain Sean | Chief Executive Officer |
Feb 02 '26 |
Sale |
2.99 |
26,761 |
80,015 |
8,334,567 |
| Jonasson Zachariah | CFO / CBO |
Feb 02 '26 |
Sale |
2.99 |
17,496 |
52,313 |
383,538 |
| VAN HOUTEN FRANS | Director |
Dec 05 '25 |
Buy |
3.72 |
40,000 |
148,800 |
63,320 |
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):